Fluoxetine HCl price index

Fluoxetine HCl price December 2025 and outlook (see chart below)

• India:US$85.25/KG, -2.4% down

Business Analytiq assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness.

Fluoxetine HCl price index

This post is a summary of the Fluoxetine HCl price developments. The price developments of Fluoxetine HCl are expressed in US$ prices converted FX rates applicable at the time when the price was valid. Fluoxetine HCl price index developments are calculated from multiple separate sources of data to ensure statistical accuracy.

The outlook for Fluoxetine HCl prices is generated from different inputs including:

• Very recent price developments of immediate cost drivers of Fluoxetine HCl prices
• Recent price developments of underlying feedstocks which drive the price of Fluoxetine HCl
• Market futures for both cost drives and feedstocks of Fluoxetine HCl prices
• Adjustment of current supply/demand imbalances in the Fluoxetine HCl market
• Longer term trends in likely demand conditions

What is Fluoxetine HCl and what is it used for

Fluoxetine HCl (fluoxetine hydrochloride) is a medication in the class of selective serotonin re-uptake inhibitors (SSRIs). It works by inhibiting the re-uptake of serotonin in the brain, thereby increasing serotonin levels in the synaptic cleft and influencing mood and emotional regulation. The drug is widely used to treat major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, panic disorder, and premenstrual dysphoric disorder (PMDD).

How is Fluoxetine HCl produced

The production of fluoxetine hydrochloride involves synthetic organic chemistry because it is an active pharmaceutical ingredient (API). For example, the free base fluoxetine is converted to the hydrochloride salt (fluoxetine HCl) to improve its crystalline form and stability. API manufacturers list fluoxetine HCl under synthetic API production.

Finished dosage forms (tablets, capsules, oral solutions) are then manufactured by pharmaceutical companies under Good Manufacturing Practice (GMP) standards. For instance, one manufacturer states that their fluoxetine HCl tablets are produced in GMP-certified facilities in India, China and the USA.

How large is the global market for Fluoxetine HCl and where is it produced

The global market for fluoxetine HCl (and more broadly fluoxetine) is estimated to be in the **USD 1.5-2.5 billion** range in the mid-2020s, with forecasts indicating growth to ~USD 2.5 billion by ~2033 under some reports.

Another source estimates the fluoxetine (generic plus branded) market at ~USD 12.9 billion in 2024, growing to ~USD 16.8 billion by 2035 — though this may include broader formulations and related products. It appears the fluoxetine HCl specific market is smaller and more narrowly defined. One report gives ~USD 1.8369 billion for 2024.

In terms of production geography: a large share of API manufacturing is located in India and China, which are major global suppliers of pharmaceutical APIs.

Specific API manufacturers for fluoxetine HCl include Dr. Reddy’s Laboratories (India) providing the fluoxetine API globally.

Finished-dosage manufacturing is also undertaken in India, China and the USA. Furthermore, regulatory supply-chain analyses show that many pharmaceutical APIs are produced in Asia (China, India) and then finished into drugs for global markets.

In summary: fluoxetine HCl is a widely used SSRI antidepressant; its manufacture involves API synthesis (often in India/China) followed by tablet/capsule production; its global market is in the low billions USD; and major production centres are India, China and also finished product plants in other regulated markets.